Brian Holmes, who has been battling metastatic prostate cancer, underwent the pioneering treatment at Derriford Hospital ...
The GPS Mdx test is a 17-gene expression assay performed on prostate biopsy tissue that may identify signals of favorable vs unfavorable pathology.
While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...
Pfizer (PFE) stock is in focus as Xtandi, marketed with Astellas (ALPMF), and cancer drug Talzenna succeed in a Phase 3 trial for prostate cancer. Read more here.
Betsi Cadwaladr University Health Board’s CEO apologised 'for the unacceptable delays' ...
Ibex Medical Analytics (Ibex), the global leader in clinical-grade AI-powered pathology, today announced the launch of Ibex 4, its next-generation platform. Built on Ibex's clinic ...
This is a rare opportunity for me personally, this is my only hope to extend my life by any real period at all." ...
One of oncology's biggest challenges is that the same treatment can work well for some patients but fail completely in others.
Dr. Bertrand Tombal delivered a practical presentation titled “What Do You Need for Decision Making in mHSPC in 2026?”, focusing on how contemporary therapeutic choices in metastatic hormone-sensitive ...
Healthcare provider, LivingCare Group has been selected as the proposed imaging partner for the IMProVE clinical trial, a prostate cancer early-detection programme funded by Yorkshire Cancer Research.
Dr. Fizazi began by revisiting the role of docetaxel in the mHSPC setting, emphasizing that treatment benefit varies ...
Mdxhealth Highlights Data from Oxford’s ProMPT Study Demonstrating the Genomic Prostate Score GPS Test Predicts Adverse Outcomes Across Multiple Treatment Settings at EAU 2026 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results